BeiGene, Ltd/$ONC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BeiGene, Ltd
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Ticker
$ONC
Sector
Primary listing
Employees
11,000
Headquarters
Basel, Switzerland
Website
BeiGene, Ltd Metrics
BasicAdvanced
$38B
594.69
$0.58
-
-
Price and volume
Market cap
$38B
52-week high
$385.22
52-week low
$174.74
Average daily volume
266K
Financial strength
Current ratio
2.392
Quick ratio
2.085
Long term debt to equity
4.624
Total debt to equity
24.701
Interest coverage (TTM)
6.93%
Profitability
EBITDA (TTM)
328.171
Gross margin (TTM)
86.19%
Net profit margin (TTM)
1.38%
Operating margin (TTM)
3.66%
Effective tax rate (TTM)
62.39%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
1.69%
Return on equity (TTM)
1.81%
Valuation
Price to earnings (TTM)
594.687
Price to revenue (TTM)
7.561
Price to book
9.32
Price to tangible book (TTM)
9.46
Price to free cash flow (TTM)
81.05
Free cash flow yield (TTM)
1.23%
Free cash flow per share (TTM)
4.29
Growth
Revenue change (TTM)
50.43%
Earnings per share change (TTM)
-107.43%
3-year revenue growth (CAGR)
58.46%
10-year revenue growth (CAGR)
97.45%
3-year earnings per share growth (CAGR)
-69.83%
10-year earnings per share growth (CAGR)
-17.63%
BeiGene, Ltd News
AllArticlesVideos
This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452%
Investors Business Daily3 days ago
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
Business Wire4 days ago
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BeiGene, Ltd stock?
BeiGene, Ltd (ONC) has a market cap of $38B as of November 24, 2025.
What is the P/E ratio for BeiGene, Ltd stock?
The price to earnings (P/E) ratio for BeiGene, Ltd (ONC) stock is 594.69 as of November 24, 2025.
Does BeiGene, Ltd stock pay dividends?
No, BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders as of November 24, 2025.
When is the next BeiGene, Ltd dividend payment date?
BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene, Ltd?
BeiGene, Ltd (ONC) does not currently have a Beta indicator.